| Document |
Document Title |
|
WO/2019/190999A1 |
Disclosed herein are methods of treating fibrotic disorders by administering compounds selective for CAPN1, CAPN2, and/or CAPN9 such that side effects, off pathway interactions, and/or toxicities are minimized. Such methods may, for exam...
|
|
WO/2019/174589A1 |
Disclosed herein a crystal structure of a caspase inhibitor, and more specifically a crystal structure of an (S)-3-((S)-2-(5-(2-chlorobenzyl) isoxazole-3-formyl amide) proponamide)-4-oxo-5-(2,3,5,6-tetraphenoxy)) valeric acid, a preparat...
|
|
WO/2019/165967A1 |
A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases.
|
|
WO/2019/160813A1 |
The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present inv...
|
|
WO/2019/156903A1 |
Disclosed are compounds of Formula 1, wherein J is and R1a, R1b, R2, R3, R4, R5, R6, R7, R8, R14, R15, R16, Q and X are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for c...
|
|
WO/2019/145245A1 |
The invention relates to 3-phenylisoxazoline-5-carboxamides of cyclopentenyl carboxylic acid derivatives of the general formula (I) and their agrochemically acceptable salts (I), and to the use thereof in the field of plant protection.
|
|
WO/2019/142191A1 |
Novel compounds capable of inhibiting methionine metabolic pathway are provided. These compounds are used in inhibiting cystathionin y-synthase (CGS) in general, and in plants, fungi and bacteria, in particular. These compounds of the in...
|
|
WO/2019/136147A1 |
Di- and triaryl-substituted heteroaromatic compounds have Toll-like receptor inhibitory activity, including at TLR2, TLR4, TLR7, and/or TLR9. Compounds and compositions have applications in the treatment of diseases and conditions mediat...
|
|
WO/2019/131715A1 |
The present disclosure provides an industrially preferable, economical, and environmentally friendly method for producing a compound (C1) of formula (5), namely, a (4, 5-dihydroisooxazol -3-yl)thiocarboxamidine salt compound. The present...
|
|
WO/2019/121394A1 |
The present invention relates to solid forms of the insecticide of formula (I): compositions comprising the solid forms and methods of their use as insecticides.
|
|
WO/2019/126084A1 |
The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no mo...
|
|
WO/2019/123375A1 |
This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use therof for treatment of a neurological disorder.
|
|
WO/2019/126613A1 |
Provides herein are novel compounds, compositions, and methods useful for inhibiting bacteria, such as Mycobacterium tuberculosis. These compositions and methods find many uses in medicine and research, e.g., treating subjects afflicted ...
|
|
WO/2019/126099A1 |
The present invention provides compounds of Formula (Ia) and (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are se...
|
|
WO/2019/126086A1 |
The present invention provides compounds of Formula (Ia) or (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are sel...
|
|
WO/2019/123378A1 |
This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use therof for treatment of a neurological disorder.
|
|
WO/2019/115781A1 |
The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit t...
|
|
WO/2019/117255A1 |
The present invention addresses the problem of providing an industrially preferable, economical, and environmentally friendly method for producing the 4,5-dihydroisoxazole represented by a formula (3). The present invention enables the c...
|
|
WO/2019/109132A1 |
The present invention relates generally to chemical compounds and methods for their use and preparation. In particular, the invention relates to chemical compounds which are useful in relation to the treatment of diseases, disorders or c...
|
|
WO/2019/113542A1 |
Described herein are heterocycle substituted pyridine derivative antifungal agents and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of fungal diseases and infe...
|
|
WO/2019/106584A1 |
An object of the present invention is to provide an isoxazole compound or a salt thereof that controls pests. The present invention provides an isoxazole compound represented by Formula (I), or a salt thereof, wherein R represents C1-6 a...
|
|
WO/2019/096241A1 |
Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I).
|
|
WO/2019/091940A1 |
The application relates to a process to produce large isoxazoline compound particles which comprises initiating crystallization and then maintaining the temperature of the crystallization in the metastable region by removing, reheating a...
|
|
WO/2019/091936A1 |
An injectable pharmaceutical composition comprising an isoxazoline compound of Formula (I) or a salt or N-oxide thereof wherein the isoxazoline compound has a particle size of from about 25 microns to about 250 microns and a method of pr...
|
|
WO/2019/090069A1 |
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/089672A1 |
The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farn...
|
|
WO/2019/090074A1 |
Provided herein are compounds of formula (I) and (II), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/089667A1 |
The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farn...
|
|
WO/2019/090076A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/089665A1 |
The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of far...
|
|
WO/2019/068947A1 |
Use of the compound Ki16425 for preventing, relieving, improving and/or treating alcohol-related mental and behavioural disorders, including harmful or high-risk use, alcohol intoxication or pathological drunkenness, alcohol dependence s...
|
|
WO/2019/057969A1 |
The present invention relates to small molecule compounds and their use as agonists of farnesoid X receptor (FXR) and/or peroxisome proliferator activated receptor delta (PPARĪ“). The present invention also relates to the use of said com...
|
|
WO/2019/054430A1 |
The purpose of the present invention is to provide a compound having an anti-inflammatory action, a pharmacologically acceptable salt thereof, etc. A solving means of the present invention is a compound of general formula (1) or a pharma...
|
|
WO/2019/051396A1 |
Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: formula (I), wherein A is N or CR...
|
|
WO/2019/034059A1 |
The present invention relates to a compound and the application thereof in treating inflammation or inflammation-related diseases, and more specifically to a compound UTLOH combination. Said compound effectively inhibits the level of LPS...
|
|
WO/2019/034602A1 |
The invention relates to 3-phenyl-5-trifluoromethylisoxazoline-5-carboxamides of cyclopentylcarboxylic acids and esters of general formula (I) and the agrochemically acceptable salts thereof and to the use thereof in the field of plant p...
|
|
WO/2019/030177A1 |
The present invention relates to crystal forms of 2-[(2,4-dichlorophenyl)methyl]-4,4-dimefhyl- isoxazolidin-3-one, a method for preparing these crystal forms, use thereof in agrochemical formulations and also particular compositions, mix...
|
|
WO/2019/014748A1 |
Methods for prevention and treatment of asthma attacks involve the administration of one or more TRPV1 antagonists, one or more LPAr antagonists or preferably a combination of one or more TRPV1 antagonists and one or more LPAr antagonist...
|
|
WO/2019/001361A1 |
A piperic acid derivative and preparation and an application thereof. The structure of the derivative is as shown in general formula I. The compound of general formula I has excellent pesticidal, miticidal, and bactericidal activities an...
|
|
WO/2018/233728A1 |
Provided in the present application are benzo[d]isoxazole compounds, a preparation method therefor and an application thereof. The benzo[d]isoxazole compounds are a group of compounds having novel structures and which act as bromodomain ...
|
|
WO/2018/232491A1 |
There is described herein compound comprising a mitochondrial targeting portion, a cargo portion including a drug unit, and a linker conjugating the mitochondrial targeting portion and the cargo portion, the linker portion cleavable in a...
|
|
WO/2017/191000A9 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2018/230528A1 |
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...
|
|
WO/2018/219204A1 |
The present invention relates to a novel phenoxyacetic acid derivative represented by general formula (I), a preparation method for the derivative and uses of drug compositions containing the derivative in drug preparation for treatment ...
|
|
WO/2018/215818A1 |
The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and...
|
|
WO/2018/202487A1 |
The present invention relates to 5-(haloalkyl)-5-hydroxy-isoxazoles of the formula (I), or the N-oxides, or the agriculturally useful salts thereof, and the use thereof for controlling phytopathogenic fungi; to a method for combating phy...
|
|
WO/2018/191871A1 |
Disclosed in the present invention is a method for use in preparing an isoxazoline derivative: an olefin derivative, a diazo derivative and tert-Butyl nitrite are used as a reaction substrate, while a copper compound is used as a catalys...
|
|
WO/2018/190643A1 |
The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazol...
|
|
WO/2018/187623A1 |
The present invention provides crystalline forms of compound of formula (la) and processes of making the crystalline forms. Also provided are compositions comprising the crystalline forms and crystalline forms for treating or preventing ...
|
|
WO/2018/186365A1 |
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...
|
